194 related articles for article (PubMed ID: 36430972)
1. MicroRNA Expression Profile in TSC Cell Lines and the Impact of mTOR Inhibitor.
Pawlik B; Grabia S; Smyczyńska U; Fendler W; Dróżdż I; Liszewska E; Jaworski J; Kotulska K; Jóźwiak S; Młynarski W; Trelińska J
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430972
[TBL] [Abstract][Full Text] [Related]
2. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications.
Trelinska J; Fendler W; Dachowska I; Kotulska K; Jozwiak S; Antosik K; Gnys P; Borowiec M; Mlynarski W
Orphanet J Rare Dis; 2016 Sep; 11(1):129. PubMed ID: 27680012
[TBL] [Abstract][Full Text] [Related]
3. [MicroRNA differential expression profile in tuberous sclerosis complex cell line TSC2
Cai Y; Guo H; Li HZ; Wang WD; Zhang YS
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):580-584. PubMed ID: 28816269
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
[TBL] [Abstract][Full Text] [Related]
5. mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile.
Pawlik B; Smyczyńska U; Grabia S; Fendler W; Dróżdż I; Bąbol-Pokora K; Kotulska K; Jóźwiak S; Borkowska J; Młynarski W; Trelińska J
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743464
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
7. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
8. miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma.
Cai Y; Wang W; Guo H; Li H; Xiao Y; Zhang Y
Lab Invest; 2018 Jul; 98(7):856-870. PubMed ID: 29540858
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex.
Yang F; Yang L; Wataya-Kaneda M; Hasegawa J; Yoshimori T; Tanemura A; Tsuruta D; Katayama I
J Dermatol Sci; 2018 Feb; 89(2):155-164. PubMed ID: 29146131
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
11. A brain proteomic investigation of rapamycin effects in the
Wesseling H; Elgersma Y; Bahn S
Mol Autism; 2017; 8():41. PubMed ID: 28775826
[TBL] [Abstract][Full Text] [Related]
12. Is mTOR inhibition a systemic treatment for tuberous sclerosis?
Moavero R; Coniglio A; Garaci F; Curatolo P
Ital J Pediatr; 2013 Sep; 39():57. PubMed ID: 24044547
[TBL] [Abstract][Full Text] [Related]
13. Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paraganglioma.
Calsina B; Castro-Vega LJ; Torres-Pérez R; Inglada-Pérez L; Currás-Freixes M; Roldán-Romero JM; Mancikova V; Letón R; Remacha L; Santos M; Burnichon N; Lussey-Lepoutre C; Rapizzi E; Graña O; Álvarez-Escolá C; de Cubas AA; Lanillos J; Cordero-Barreal A; Martínez-Montes ÁM; Bellucci A; Amar L; Fernandes-Rosa FL; Calatayud M; Aller J; Lamas C; Sastre-Marcos J; Canu L; Korpershoek E; Timmers HJ; Lenders JW; Beuschlein F; Fassnacht-Capeller M; Eisenhofer G; Mannelli M; Al-Shahrour F; Favier J; Rodríguez-Antona C; Cascón A; Montero-Conde C; Gimenez-Roqueplo AP; Robledo M
Theranostics; 2019; 9(17):4946-4958. PubMed ID: 31410193
[No Abstract] [Full Text] [Related]
14. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
15. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
[TBL] [Abstract][Full Text] [Related]
16. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex.
Kenerson H; Dundon TA; Yeung RS
Pediatr Res; 2005 Jan; 57(1):67-75. PubMed ID: 15557109
[TBL] [Abstract][Full Text] [Related]
17. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex.
Zeng LH; Rensing NR; Zhang B; Gutmann DH; Gambello MJ; Wong M
Hum Mol Genet; 2011 Feb; 20(3):445-54. PubMed ID: 21062901
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
19. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
